Active — Not RecruitingPhase 1

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

United States40 participantsStarted 2026-02-11

Plain-language summary

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters. * Body weight \>= 35 kg. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis. * Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration. * Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration. * Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants with Adverse Events (AEs)

Timeframe: Up to At Least 3 Months

Maximum Observed Serum Concentration (Cmax) of ABBV-8736

Timeframe: Up to At Least 3 Months

Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736

Timeframe: Up to At Least 3 Months

Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736

Timeframe: Up to At Least 3 Months

AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736

Timeframe: Up to At Least 3 Months

Terminal Phase Elimination Rate Constant (β) of ABBV-8736

Timeframe: Up to At Least 3 Months

Terminal Elimination Half-Life (t1/2) of ABBV-8736

Timeframe: Up to At Least 3 Months

Trial details

NCT IDNCT07413133

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Healthy Volunteer trials

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of Participants with Adverse Events (AEs)

Timeframe: Up to At Least 3 Months

Maximum Observed Serum Concentration (Cmax) of ABBV-8736

Timeframe: Up to At Least 3 Months

Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736

Timeframe: Up to At Least 3 Months

Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736

Timeframe: Up to At Least 3 Months

AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736

Timeframe: Up to At Least 3 Months

Terminal Phase Elimination Rate Constant (β) of ABBV-8736

Timeframe: Up to At Least 3 Months

Terminal Elimination Half-Life (t1/2) of ABBV-8736

Timeframe: Up to At Least 3 Months